Development of Biosimilars episode artwork

EPISODE · Jul 13, 2023 · 27 MIN

Development of Biosimilars

from RhAPPcast

Join us for the second episode of the GHAPP & RhAPP Biosimilar Podcast Series, where host Amanda Mixon, PA-C, sits down with Tanya Golovanoff, PharmD, to explore the intricate world of biosimilar development. As biosimilars continue to reshape the treatment landscape in rheumatology and gastroenterology, understanding their development process is essential for healthcare providers navigating this evolving field.This episode takes a deep dive into the scientific and regulatory journey behind biosimilars, breaking down the extensive research, rigorous clinical testing, and advanced manufacturing techniques that ensure these therapies match the safety and efficacy of their reference biologics. The discussion sheds light on the analytical testing required to establish biosimilarity, the importance of immunogenicity assessments, and the real-world implications of biosimilars in clinical practice. With rheumatology and gastroenterology providers at the forefront of patient education, the conversation also highlights the importance of understanding biosimilar naming conventions, explaining the rationale behind the structured FDA suffix system and how it impacts prescribing.Biosimilars offer a promising avenue for increasing patient access to biologic therapies while reducing healthcare costs. However, ensuring a smooth transition for patients requires APPs to stay informed and confident in explaining the role of biosimilars in treatment plans. As insurance mandates shift prescribing patterns, the need for clarity around biosimilars has never been more critical. Tanya Golovanoff’s expertise provides a clear and compelling perspective on how biosimilars are developed, manufactured, and named, offering valuable insights for healthcare providers managing treatment decisions in gastroenterology, rheumatology, and immunology.Tune in to this engaging discussion and stay ahead of the latest advancements in biosimilars. Subscribe to GHAPP & RhAPPcast on your favorite podcast platform and explore expert-driven resources on the RhAPP ACE App to enhance your clinical knowledge and support optimal patient care.Please take our evaluation regarding this podcast here: https://www.rhapp.org/bio-podcast-eval

Episode metadata supplied by the publisher feed · Published Jul 13, 2023

Embed this episode

Join us for our second episode of the GHAPP and RhAPP biosimilar podcast series! In this episode host Amanda Mixon, PA-C discusses the Development of Biosimilars with our esteemed guest Tanya Golovanoff, PharmD.The learning objectives and goals for this episode are to:-Distill the immense amount of research and development that occurs to develop biosimilars-Articulate the biosimilar manufacturing process -Explain how biosimilars are namedPlease take our evaluation regarding this podcast her...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Development of Biosimilars

0:00 27:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RhAPPcast?

This episode is 27 minutes long.

When was this RhAPPcast episode published?

This episode was published on July 13, 2023.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this RhAPPcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!